Three questions from my end. If you could give us some details on the Brazil acquisition in terms of the categories the target operates in, what is the revenue and what's the acquisition cost like that you've paid? And on the current acquisitions that were made, Citieffe and PendraCare, is it fair to assume that most of their sales, which you highlighted broadly about INR65 crores this quarter are in EU itself? Or is there an EU and ROW sort of split there? If you could give us that and accordingly to understand what the organic performance on EU and ROW is? And on your guidance of 15% to 17% stand-alone growth, could you give us a sense of how would that pan out domestically versus for exports and for the core infusion therapy versus the new therapies?
Got it. Just a follow-up on that, given how that's panned out. In terms of the headwinds that you saw this year in Europe, how are you seeing the situation on ground now? And when do you expect -- at what point in time in FY '27 or whenever do you expect this to normalize?